MARKET

PROF

PROF

Profound Med Corp
NASDAQ
7.01
-0.24
-3.31%
After Hours: 7.19 +0.18 +2.57% 19:30 10/13 EDT
OPEN
7.19
PREV CLOSE
7.25
HIGH
7.19
LOW
6.84
VOLUME
374.25K
TURNOVER
--
52 WEEK HIGH
8.95
52 WEEK LOW
4.800
MARKET CAP
256.09M
P/E (TTM)
-7.0873
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PROF last week (1005-1009)?
Weekly Report · 1d ago
Profound Medical, Telix Join Forces to Advance PSMA-Guided Prostate Care
TipRanks · 4d ago
Profound Medical: Q3 Revenue Beats Outlook (Rating Upgrade)
Seeking Alpha · 4d ago
Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate Care
NASDAQ · 4d ago
Profound Medical enters co-education agreement with Telix Pharmaceuticals
TipRanks · 4d ago
Profound Medical Signs Agreement With Telix Pharmaceuticals To Educate Urologists, Radiologists, Nuclear Medicine Physicians, Prostate Cancer Centers Over Roles Of Telix’s Advanced Prostate-Specific Membrane Antigen
Benzinga · 4d ago
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
NASDAQ · 4d ago
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Barchart · 4d ago
More
About PROF
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Webull offers Profound Medical Corp stock information, including NASDAQ: PROF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PROF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PROF stock methods without spending real money on the virtual paper trading platform.